Cargando…

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies

BACKGROUND: Chronic psoriasis may require medication adjustments over time. OBJECTIVES: To evaluate the efficacy/safety of tildrakizumab in subgroups from the reSURFACE studies (N = 1862) that received continuous dosing, higher/lower dosing, treatment interruption/reinitiation and initiation. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimball, A.B., Papp, K.A., Reich, K., Gooderham, M., Li, Q., Cichanowitz, N., La Rosa, C., Blauvelt, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317753/ https://www.ncbi.nlm.nih.gov/pubmed/31487406 http://dx.doi.org/10.1111/bjd.18484

Ejemplares similares

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab
por: Kimball, A.B., et al.
Publicado: (2019)

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials
por: Blauvelt, A., et al.
Publicado: (2019)

The safety of etanercept for the treatment of plaque psoriasis
por: Papp, Kim A
Publicado: (2007)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis
por: Blauvelt, A., et al.
Publicado: (2017)

Etanercept in the treatment of plaque psoriasis
por: Nguyen, Thao U, et al.
Publicado: (2009)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
por: Burlando, Martina, et al.
Publicado: (2021)

Erythrodermic psoriasis improved by Tildrakizumab
por: Trevisan, Giampaolo, et al.
Publicado: (2022)

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
por: Gottlieb, AB, et al.
Publicado: (2012)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
por: Beck, Kristen M, et al.
Publicado: (2018)

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
Publicado: (2021)

Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor
por: Gooderham, M., et al.
Publicado: (2019)

Tildrakizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study
por: Caldarola, Giacomo, et al.
Publicado: (2022)

Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study
por: Menter, M.A., et al.
Publicado: (2020)

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis
por: Gordon, K.B., et al.
Publicado: (2021)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
por: Näslund-Koch, Charlotte, et al.
Publicado: (2020)

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)
por: Reich, K., et al.
Publicado: (2016)

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
por: Pithadia, Deeti J., et al.
Publicado: (2019)

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
por: Papp, K.A., et al.
Publicado: (2018)

Phase I randomized study of KHK4083, an anti‐OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis
por: Papp, K.A., et al.
Publicado: (2017)

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
por: Megna, Matteo, et al.
Publicado: (2021)

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
por: Blauvelt, Andrew, et al.
Publicado: (2017)

A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis
por: Becher, Gabrielle, et al.
Publicado: (2022)

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis
por: Carrico, Justin, et al.
Publicado: (2020)

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
por: Blauvelt, Andrew, et al.
Publicado: (2018)

Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)
por: Narcisi, Alessandra, et al.
Publicado: (2022)

Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials
por: Blauvelt, A., et al.
Publicado: (2018)

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)
por: Papp, KA, et al.
Publicado: (2015)

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE
por: Papp, K.A., et al.
Publicado: (2015)

A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
por: Damsin, Thomas
Publicado: (2023)

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study
por: Reich, K., et al.
Publicado: (2018)

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
por: van der Schoot, L.S., et al.
Publicado: (2023)

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
por: Tan, H, et al.
Publicado: (2013)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
por: Gooderham, M.J., et al.
Publicado: (2018)

Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT
por: Tsianakas, Athanasios, et al.
Publicado: (2022)

Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review
por: Gambardella, Alessio, et al.
Publicado: (2021)

Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis
por: Ruano, Juan, et al.
Publicado: (2013)

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks
por: Reich, K., et al.
Publicado: (2019)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g0apa14el6e5vift1u1tpo6tvj